Clinical risk groups are defined Tables 3 and 4 of chapter 14a of the Green Book. 5-17 year olds in a clinical risk group.In July 2022, JCVI advised that booster doses of should be offered in the Autumn 2022 to: 12-15 year olds who are severely immunosuppressed and have had a third primary dose.12-15 year olds who are household contacts of someone who is immunosuppressed.12-15 year olds in a clinical risk group.On 22 December 2021, JCVI advised that booster doses of 30mcg of Pfizer-BioNTech should be offered no sooner than 3 months after completing the primary doses to: What about booster doses for children and young people? ** criteria for a third primary dose are listed in Box 1 and Box 2 in the Green Book chapter on COVID-19 * clinical risk as defined in Table 4 of the Green Book chapter on COVID-19
Note: The Green Book provides advice on dosing intervals following recent COVID-19 infection Two 30 mcg doses of Pfizer-BioNTech, at least 12 weeks apart Three 30mcg doses of Pfizer-BioNTech, at least 8 weeks apartĪ specialist paediatrician should advise whether the child or young person meets the eligibility criteria and on the timing of the third doseġ2-17 year olds not in groups specified above Two 30mcg doses of Pfizer-BioNTech, at least 12 weeks apartġ2-17 year olds who are severely immunosuppressed** Two 30mcg doses of Pfizer-BioNTech, at least 8 weeks apartġ2-17 year olds who are household contacts of someone who is immunosuppressed
Note: For 5-11 year olds above, JCVI advise that there should be a minimum four-week interval between any vaccine dose and recent COVID-19 infection Two 10 mcg doses of Pfizer BioNTech, at least 12 weeks apart Three 10mcg doses of Pfizer-BioNTech, at least 8 weeks apartĥ-11 year olds not in groups specified above. This one-off programme includes children who turn 5 years old before the end of August 2022. Two 10mcg doses of Pfizer-BioNTech, at least 8 weeks apartĥ-11 year olds who are household contacts of someone who is immunosuppressedĥ-11 year olds who are severely immunosuppressed** The JCVI’s advice on primary doses is as follows. Since July 2021, the Joint Committee on Vaccination and Immunisation (JCVI) and the UK Chief Medical Officers (CMOs) have been advising on how the COVID-19 vaccination programme may be applied to children and young people. This advice covers primary doses and booster doses. Updated: 6 September 2022 Who will be offered COVID-19 vaccinations?
0 kommentar(er)
